Birdwatch Archive

Birdwatch Note

2023-02-28 01:27:01 UTC - MISINFORMED_OR_POTENTIALLY_MISLEADING

"Although raw numbers were not presented in the paper the primary outcome differed by a total of just 20 cases between the treatment and control arms: In a study population of over 300,000 individuals there were 1106 symptomatic seropositives in control and 1086 in treatment." https://trialsjournal.biomedcentral.com/articles/10.1186/s13063-022-06704-z

Written by DA1CE6B5155F4FB13AE546958A7A0E460080B24340952155667FC47868ECE445
Participant Details

Original Tweet

Tweet embedding is no longer reliably available, due to the platform's instability (in terms of both technology and policy). If the Tweet still exists, you can view it here: https://twitter.com/foo_bar/status/1630000813450964993

Please note, though, that you may need to have your own Twitter account to access that page. I am currently exploring options for archiving Tweet data in a post-API context.

All Information

  • ID - 1630379007525920768
  • noteId - 1630379007525920768
  • participantId - DA1CE6B5155F4FB13AE546958A7A0E460080B24340952155667FC47868ECE445
  • noteAuthorParticipantId -
  • createdAtMillis - 1677547621031
  • tweetId - 1630000813450964993
  • classification - MISINFORMED_OR_POTENTIALLY_MISLEADING
  • believable -
  • harmful -
  • validationDifficulty -
  • misleadingOther - 0
  • misleadingFactualError - 0
  • misleadingManipulatedMedia - 0
  • misleadingOutdatedInformation - 0
  • misleadingMissingImportantContext - 1
  • misleadingUnverifiedClaimAsFact - 0
  • misleadingSatire - 0
  • notMisleadingOther - 0
  • notMisleadingFactuallyCorrect - 0
  • notMisleadingOutdatedButNotWhenWritten - 0
  • notMisleadingClearlySatire - 0
  • notMisleadingPersonalOpinion - 0
  • trustworthySources - 1
  • summary
    • "Although raw numbers were not presented in the paper the primary outcome differed by a total of just 20 cases between the treatment and control arms: In a study population of over 300,000 individuals there were 1106 symptomatic seropositives in control and 1086 in treatment." https://trialsjournal.biomedcentral.com/articles/10.1186/s13063-022-06704-z

Note Status History

createdAt timestampMillisOfFirstNonNMRStatus firstNonNMRStatus timestampMillisOfCurrentStatus currentStatus timestampMillisOfLatestNonNMRStatus mostRecentNonNMRStatus participantId
2023-02-28 01:27:01 UTC
(1677547621031)
1969-12-31 23:59:59 UTC
(-1)
2023-03-07 02:11:29 UTC
(1678155089929)
NEEDS_MORE_RATINGS 1969-12-31 23:59:59 UTC
(-1)

Note Ratings

rated at rated by
2023-02-27 20:56:27 -0600 0AD9DC83091CCD638FEA2C5486DBAFFEB24C6D23C499F284C80BF60D3E54AE95 Rating Details
2023-02-28 18:09:45 -0600 0D476FB8162A0B894FADC488B9348FFA9313C980B22262F5BC4C4D30F5AA0BC0 Rating Details
2023-02-28 03:22:54 -0600 251AC165CB5ED83F4E14DDCD4B8093F263B74DF7BAD439D346626E95C30F3D4B Rating Details
2023-02-28 04:13:46 -0600 2B4B21671FBEF5C1BC6D6267837E7235ACC20986970C9A5B56CA86ADB2FB9E0B Rating Details
2023-02-28 02:55:42 -0600 2EBF26F60F3A7E9005DA089FC61E341428510E1CA440226B1C2CB0CD463748D6 Rating Details
2023-02-28 06:27:35 -0600 351C24F925739877A4D8AB18810FE42663D18EA7B0316DDAD6CE5513BD192816 Rating Details
2023-02-28 18:39:44 -0600 386CBA97FA2604BB5BFB206F36315DCC46BA97CE97CBFEFADC262EEDFBA93D1A Rating Details
2023-02-27 22:15:13 -0600 43C0C6E62BBB03EF795C48F090C5C67A52516FE15C8B571592C9BE8300DFD93E Rating Details
2023-02-28 02:11:12 -0600 4CCDD7AF764C9F6485C92DCB3D585A1937F7D26C5DE4747A537177F84A5C4395 Rating Details
2023-02-28 13:28:12 -0600 4E9ED2B88C89FCE13BE6D40C0615D510C7FAA4CF0923DBA3E8945CCB20A8E82E Rating Details
2023-02-27 19:55:23 -0600 4EFE941EEE443BB7CC6EE07F79670B2B14FD67012FCF750117419F5C64A9B567 Rating Details
2023-02-28 13:14:10 -0600 5F70567B58C0AD8B38AE064172F7358F84DA61D6E07139A62A16F57A4EBA2A57 Rating Details
2023-02-27 19:36:20 -0600 65109B6CBF27037A850CDCFD1D120D151FC44AA7666864FA5B40F5BF0CC87BD4 Rating Details
2023-02-27 19:41:26 -0600 7D54F22CE3B73B5239B8B38D0C45AFA9777CC59E2DB07203A1CF2C8759343BE5 Rating Details
2023-02-28 07:46:42 -0600 95B846B262167637B241A05FA2D748F27F442B3EE06DE5D0CBFD3F97E0DFD75E Rating Details
2023-02-28 09:15:30 -0600 9B559AA6B09B99FEA94168488D83194CC3D7D90C12457AC7E7F46D04005D29B2 Rating Details
2023-03-05 11:10:15 -0600 A861844748BF0CA637470389721039969DDDD03266E73A16BE6D5E42C702DDA8 Rating Details
2023-02-27 19:29:14 -0600 AA10D49699E6620C77603388B971BA6E8F4081D4FF8595A608AA94ACAC6F160E Rating Details
2023-02-28 02:50:57 -0600 B289B7B9A72A2B21A5016714B5CFECC892B67D4EF528AD49D229201250F7B83A Rating Details
2023-02-28 13:28:12 -0600 Rating Details
2023-02-28 18:09:45 -0600 Rating Details
2023-02-27 20:56:27 -0600 Rating Details
2023-02-28 09:15:30 -0600 Rating Details
2023-02-27 22:15:13 -0600 Rating Details
2023-02-27 19:55:23 -0600 Rating Details
2023-02-28 18:39:44 -0600 Rating Details
2023-02-28 04:13:46 -0600 Rating Details
2023-02-28 06:27:35 -0600 Rating Details
2023-02-28 02:11:12 -0600 Rating Details
2023-03-05 11:10:15 -0600 Rating Details
2023-02-27 19:36:20 -0600 Rating Details
2023-02-28 13:14:10 -0600 Rating Details
2023-02-27 19:29:14 -0600 Rating Details
2023-02-28 02:55:42 -0600 Rating Details
2023-02-28 03:22:54 -0600 Rating Details
2023-02-28 02:50:57 -0600 Rating Details
2023-02-27 19:41:26 -0600 Rating Details
2023-02-28 07:46:42 -0600 Rating Details